Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Avidity Biosciences (NASDAQ:RNA) and maintains a $60 price target.
August 13, 2024 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Avidity Biosciences and maintains a $60 price target.
The reiteration of a Buy rating and the maintenance of a $60 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100